Effects of vernakalant and flecainide on atrial contractility in patients with AF
- Conditions
- Patients with paroxysmal or persistent atrial fibrillation (AF) reporting at the first heart aid.Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2012-001898-90-NL
- Lead Sponsor
- Maastricht University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- patients presenting with paroxysmal or persistent AF
- eligible for treatment with flecainide or vernakalant infusion to restore sinus rhythm
- receiving adequate anticoagulant therapy (or having an episode of AF lasting < 24 hours)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30
Exclusion Criteria
- atrial flutter
- contra-indications for receiving flecainide or vernakalant infusion according to MUMC+ protocol (unstable hemodynamic condition, LVEF < 40%, inadequate potassium levels, acute ischaemia, sinus node dysfunction)
- age < 18 years
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method